ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
R

Lecture Summary - ASCO 2022 on Telisotuzumab Vedotin in Advanced c-Met Overexpressing NSCLC: Monotherapy in Previously Treated Disease; Combination With Osimertinib After Failure on Prior Osi in EGFRm Disease

By ASCO 2022 Conference Coverage FEATURING Ross Camidge
By ASCO 2022 Conference Coverage FEATURING Ross Camidge
0 views
June 14, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Lung
01:24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMa…

Feat. L. Paz-Ares
10:59
ASCO 2022 Conference Coverage

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

Feat. L. Paz-Ares
01:21
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L …

Feat. F. de Marinis
12:27
ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET…

Feat. F. de Marinis
01:08
ASCO 2022 Conference Coverage

Lecture Summary - Pralsetinib in Patients (pts) With Advanced or Met…

Feat. L. Wirth
10:01
ASCO 2022 Conference Coverage

ASCO 2022 Updated Data From the ARROW Trial: Pralsetinib in Patients…

Feat. L. Wirth
01:46
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

Feat. L. Paz-Ares
09:18
ASCO 2022 Conference Coverage

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

Feat. L. Paz-Ares
26:58
ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy Nuances in Locally Advanced NSCLC

Feat. J. Varlotto
48
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy Nuances in Locally Advance…

Feat. J. Varlotto
06:33
ASCO 2022 Conference Coverage

ASCO 2022 on Acquired EGFR-Resistant Mutations in NSCLC

Feat. L. Raez
55
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Acquired EGFR-Resistant Mutations in …

Feat. L. Raez
01:06
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Recurrent SCLC: Can We Change the Par…

Feat. R. Gentzler
01:28
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo i…

Feat. B. Chul Cho
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Ma…

Feat. B. Chul Cho
05:02
ASCO 2022 Conference Coverage

ASCO 2022 on IO and Chemo-IO for NSCLC With Novel Actionable Oncogen…

Feat. L. Mazzeo, M. Occhipinti
01:09
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Impact of Trilaciclib on Multilineage Ch…

Feat. J. Goldschmidt
14:23
ASCO 2022 Conference Coverage

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

Feat. J. Goldschmidt
04:31
ASCO 2022 Conference Coverage

ASCO 2022 Predictors of Biomarker Testing Among Pts With mNSCLC

Feat. N. Robert
06:43
ASCO 2022 Conference Coverage

ASCO 2022 on a Phase I, Open-Label, Dose Escalation, Confirmation, a…

Feat. J. Heymach
01:17
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Phase I, Open-Label, Dose Escalatio…

Feat. J. Heymach
20:37
Jia Luo

Taking on Goliath: Targeting KRAS in NSCLC

07:03
ASCO 2022 Conference Coverage

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relap…

Feat. A. Navarro
05:27
ASCO 2022 Conference Coverage

ASCO 2022 on Telisotuzumab Vedotin in Advanced c-Met Overexpressing …

Feat. R. Camidge
52
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

Feat. A. Navarro
23
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Telisotuzumab Vedotin in Advanced c-M…

Feat. R. Camidge
05:57
ASCO 2022 Conference Coverage

ASCO 2022 on TROPION-Lung08: Dato-DXd + Pembro in Treatment-Naïve Ad…

Feat. B. Levy
01:18
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

Feat. B. Besse
33
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Combi-TED: A Multicenter Phase II Trial …

Feat. F. Cappuzzo
04:36
ASCO 2022 Conference Coverage

ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficac…

Feat. F. Cappuzzo
01:01
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

Feat. K. Gaebe
15:49
ASCO 2022 Conference Coverage

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

Feat. K. Gaebe
25
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Stud…

Feat. J. Sands
04:05
ASCO 2022 Conference Coverage

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

Feat. J. Sands
24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

Feat. J. Sands
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

Feat. J. Sands
52
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Three-Year Outcomes and Correlative Anal…

Feat. B. Ricciuti
07:54
ASCO 2022 Conference Coverage

ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients W…

Feat. B. Ricciuti
07:00
ASCO 2022 Conference Coverage

ASCO 2022 on GEOMETRY-N Trial: Neoadjuvant and Adjuvant Capmatinib i…

Feat. J. Lee